MedPharm, a Guildford, UK-based topical and transdermal Contract Improvement and Manufacturing Group (CDMO) and Ampersand Capital Companions portfolio firm, introduced a merger with Tergus Pharma, a Analysis Triangle Park, NC-based end-to-end contract service supplier and a Nice Level Companions portfolio firm.
The mixed group will function underneath the MedPharm identify, establishing an end-to-end CDMO with scientific, medical trial manufacturing and business manufacturing capabilities.
As a part of this transaction, Tergus Pharma CEO Michael Kane has been appointed CEO of MedPharm whereas Patrick Walsh will proceed to function Government Chairman of MedPharm.
The merged enterprise is positioned as a participant in delivering a full suite of drug growth and manufacturing companies to innovators of all sizes targeted on advancing topical and transepithelial prescribed drugs. The strategic mixture of Tergus and MedPharm’s capabilities permits business manufacturing and serialization to current formulation growth, in vitro testing and medical manufacturing inside one built-in group. Expanded capabilities will even embody the event and manufacture of hormone-based and extremely potent medication on the firm’s GMP manufacturing facility in Durham, NC.
Tergus lead investor Nice Level Companions will retain a major minority possession stake within the newly mixed MedPharm, whereas non-public fairness corporations Ampersand Capital Companions and Bourne Companions Strategic Capital assume majority possession.
FinSMEs
08/07/2024
